<DOC>
	<DOCNO>NCT01112345</DOCNO>
	<brief_summary>The present study aim assess adherence therapy interferon beta-1a ( Rebif® ) investigate potential factor involve outcome , representative sample patient relapse remit multiple sclerosis ( RRMS ) , real life condition .</brief_summary>
	<brief_title>An Observational Study Assessment Compliance Persistence Rebif® Therapy Patients With Relapsing-remitting Multiple Sclerosis ( MS ) Evaluation Potential Factors Influencing These Parameters</brief_title>
	<detailed_description>In relapsing-remitting type disease objective therapy reduction relapse rate , duration severity , well delay transition progressive form disease . Subjects ' adherence long-term therapy MS play pivotal role optimization therapeutic outcome maximization derive clinical benefit treated subject . Rebif current formulation develop assess refine physicochemical characteristic exist formulation aim improve product 's tolerability profile . Studies perform assessment Rebif demonstrate 3-fold reduction injection site reaction well improve overall tolerability safety profile . This multicentre , prospective , non interventional , non randomize , open label study assessment adherence therapy Rebif subject RRMS . The participate subject shall already treatment ( Rebif ) prior enrolment study , accord approve Summary Product Characteristics ( SPC ) clinical , image laboratory finding disease , evaluate treat physician , real life clinical practice . Data collect retrospectively sample 150 subject ' medical file question pose subject , prospectively course study . The total duration study estimate 18 month . OBJECTIVES Primary objective : - To assess compliance persistence Rebif therapy MS subject , six month therapy , `` real life '' clinical setting Greece Secondary objective : - To investigate potential factor influence compliance persistence Rebif therapy .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Subjects document diagnosis RRMS accord Mc Donald criterion ( 2005 ) Subjects already administer therapy IFN b1a ( Rebif ) accord approve product 's Summary Product Characteristics ( SPC ) , least two week longer six week prior enrolment study Subjects gender , age 18 65 year ( inclusive ) Expanded Disability Status Scale ( EDSS ) score &lt; 6 ( inclusive ) baseline ( Rebif therapy initiation ) Subjects able read understand Patient Information Leaflet Subjects sign Informed Consent Form Subjects willing capable comply study requirement procedure . Subjects meet contraindication administration study drug accord approve SPC Subjects primary progressive secondary progressive form MS Subjects treat Rebif less two week six week enrollment study Subjects receive therapy MS ( disease modify drug , immunomodulatory and/or immunosuppressive agent ) within three month Rebif therapy commencement History chronic pain syndrome Current past ( precede two year ) history alcohol drug abuse Women pregnant breastfeed childbearing potential use medically accept method contraception Subjects currently participate participate another clinical trial last three month prior enrolment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Multiple Sclerosis , Relapsing-Remitting</keyword>
	<keyword>Interferon-beta</keyword>
</DOC>